» Articles » PMID: 10640282

Chemically Modified Oligonucleotides Exhibit Decreased Immune Stimulation in Mice

Overview
Specialty Pharmacology
Date 2000 Jan 20
PMID 10640282
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Phosphorothioate oligodeoxynucleotides produce splenomegaly and mononuclear cell infiltrates in multiple organs in mice after repeated i.v. administration. Several phosphorothioate oligodeoxynucleotides were studied to better understand the basis of immunostimulatory properties of these molecules in mice and to study the effects of chemically modified oligonucleotides. Chemical modifications examined included 5-methyl cytosine and 2'-methoxyethoxy substituents. Male mice (six per group) were treated with oligonucleotide concentrations of 0, 2, 10, or 50 mg/kg by i.v. injection every other day for 14 days. Immune stimulation was assessed 24 h after the last dose by measuring spleen weight, or histologic and immunohistochemical examination of liver and kidney. Immune stimulation was dose-dependent for the phosphorothioate oligodeoxynucleotides studied, but potency varied as a function of sequence. Results from this study reveal that there is a close correlation between the extent of splenomegaly and other evidence of immune stimulation, such as the severity of cell infiltrates in liver and kidney in mice. Immunohistochemical analysis indicated that cell infiltrates in liver and kidney were primarily mononuclear cells associated with increased expression of the endothelial-leukocyte cellular adhesion molecule intracellular adhesion molecule-1 and the cytokine interleukin-6. Immune stimulation was markedly decreased with oligonucleotides containing the 5-methyl cytosine and further decreased by 2'-methoxyethoxy modifications. Administration of these modified oligonucleotides to mice did not produce splenomegaly even at the 50-mg/kg dose, and only produced minimal cell infiltrates despite the presence of comparable or greater tissue oligonucleotide concentrations. Thus, chemical modifications appeared to increase the tolerability profile for these compounds that are representative of the second generation of antisense oligonucleotides.

Citing Articles

New approach methodologies to assess wanted and unwanted drugs-induced immunostimulation.

Bettinsoli V, Melzi G, Marchese I, Pantaleoni S, Passoni F, Corsini E Curr Res Toxicol. 2025; 8:100222.

PMID: 40027547 PMC: 11872130. DOI: 10.1016/j.crtox.2025.100222.


Preclinical assessment of splicing modulation therapy for ABCA4 variant c.768G>T in Stargardt disease.

Karjosukarso D, Bukkems F, Duijkers L, Tomkiewicz T, Kiefmann J, Sarlea A Commun Med (Lond). 2025; 5(1):25.

PMID: 39838063 PMC: 11751084. DOI: 10.1038/s43856-024-00712-7.


Technologies for Targeted RNA Degradation and Induced RNA Decay.

Mikutis S, Bernardes G Chem Rev. 2024; 124(23):13301-13330.

PMID: 39499674 PMC: 11638902. DOI: 10.1021/acs.chemrev.4c00472.


Enhancing RNA inhibitory activity using clamp-G-modified nucleobases.

Pradeep S, Kumar V, Malik S, Slack F, Gupta A, Bahal R Cell Rep Phys Sci. 2024; 5(8).

PMID: 39421604 PMC: 11484553. DOI: 10.1016/j.xcrp.2024.102120.


RNA-based medicine: from molecular mechanisms to therapy.

Sparmann A, Vogel J EMBO J. 2023; 42(21):e114760.

PMID: 37728251 PMC: 10620767. DOI: 10.15252/embj.2023114760.